Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue
Operating expenses:
Commercial operations	1,973	460	3,360	845
General and administrative	6,739	2,421	10,113	4,721
Research and development	4,258	2,133	7,573	4,702
Total operating expenses	12,970	5,014	21,046	10,268
Loss from operations	(12,970)	(5,014)	(21,046)	(10,268)
Other income (expense):
Interest expense				(52)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note		2,120	1,682	(5,888)
Offering costs - Senior Secured Convertible Note and Senior Convertible Note		(200)		(610)
Debt extinguishments loss - Senior Secured Convertible Notes		(2,750)	(3,715)	(3,937)
Debt forgiveness	300		300
Other income (expense), net	300	(830)	(1,733)	(10,487)
Loss before provision for income tax	(12,670)	(5,844)	(22,779)	(20,755)
Provision for income taxes
Net loss before noncontrolling interests	(12,670)	(5,844)	(22,779)	(20,755)
Net loss attributable to the noncontrolling interests	1,199	266	1,877	702
Net loss attributable to PAVmed Inc.	(11,471)	(5,578)	(20,902)	(20,053)
Less: Series B Convertible Preferred Stock dividends earned	(74)	(71)	(149)	(141)
Net loss attributable to PAVmed Inc. common stockholders	$ (11,545)	$ (5,649)	$ (21,051)	$ (20,194)
Per share information:
Net loss per share attributable to PAVmed Inc. - basic and diluted	$ (0.14)	$ (0.12)	$ (0.27)	$ (0.45)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted	$ (0.14)	$ (0.13)	$ (0.27)	$ (0.46)
Weighted average common shares outstanding, basic and diluted	82,235,397	44,780,538	78,117,637	44,140,126